Résultats de recherche
01 Octobre 2026 - 2 mn de lecture
When science advances, understanding must keep pace
Aurora Berra, Vice President Global Patient Officer...
20 Mai 2024 - 4 mn de lecture
Improving Diversity in Research and Development to Drive Health Equity
To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation. ...
29 Août 2023 - 2 mn de lecture
Learning the impacts of FOP from patients and their families – The Burden of Illness study
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder where extra bone formation takes place in soft tissues, including muscles, tendons and ligaments, causing irreversible and progressive loss of mobility, leading to severe disabil...
29 Août 2023 - 2 mn de lecture
Putting yourself in the shoes of someone with an ultra-rare condition: the first FOP immersive experience
You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. With this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to live with...
12 Mai 2023 - 4 mn de lecture
Understanding the true impact of living with FOP
This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23, ...
05 Septembre 2022 - 5 mn de lecture
‘A Life in a Day’: the realities of living with FOP
I was honored to be invited to take on the challenge to live ‘A Life in a Day of a patient with FOP’ – but also apprehensive. The challenge simulated a day spent living as someone who has fibrodysplasia ossificans progressiva (FOP). FOP is a debilita...
29 Juin 2022 - 6 mn de lecture
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
PARIS, France, 29 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the tre...
03 Novembre 2022 - 4 mn de lecture
A Life in a Day with FOP: from Empathy to Understanding
You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. And with this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to live ...
29 Août 2023 - 3 mn de lecture
Mieux comprendre les impacts de la FOP auprès des patients et de leurs familles – étude The Burden of Illness
La fibrodysplasie ossifiante progressive (FOP) est une maladie génétique ultra-rare caractérisée par une formation osseuse extra-squelettique dans les tissus mous, notamment les muscles, les tendons et les ligaments, qui provoque une perte de mobilité...
27 Avril 2021 - 5 mn de lecture
Working in rare disease has taught me to better support FOP
We are delighted that this FOP Awareness Day Dr Rolf Morhart shared his invaluable insights gained through his career working in clinical practice supporting people living with the ultra-rare bone disease. Read his thoughts and reflections below....